Many large pharmaceutical companies are now espousing the virtue of these strategies, but will they work if adopted inconsistently by the industry and not at all by academia and funders?
许多大型的制药公司都对以上这些战略表示拥护，但如果缺乏整个行业、学术界及一些资助机构的支持，这些战略能得以实施吗？